3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
75
HER2-positive Breast Cancer
10
Neoplasms
8
Neoplasm Metastasis
4
Colonic Neoplasms
4
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Prostatic Neoplasms
3
Multiple Myeloma
3
Hematologic Neoplasms
3
Endometrial Neoplasms
3
Brain Neoplasms
3
Anatomic Stage I Breast Cancer AJCC v8
3
Urinary Bladder Neoplasms
2
Salivary Gland Neoplasms
2
Rectal Neoplasms
2
Pathologic Complete Response
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Inflammatory Breast Neoplasms
2
HER2-positive Early Breast Cancer
2
Colorectal Neoplasms
2
Breast Diseases
2
Biliary Tract Neoplasms
2
Anatomic Stage II Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Interventions
Nivolumab
6
atezolizumab
5
Cisplatin
5
Ipilimumab
4
Carboplatin
4
Etoposide
3
pembrolizumab
2
gallium Ga 68 dotatate
2
dostarlimab
2
Temozolomide
2
Positron Emission Tomography Computed Tomography
2
Paclitaxel
2
Magnetic Resonance Imaging
2
Irinotecan
2
Immunoglobulin G
2
IFL protocol
2
Disulfides
2
zimberelimab
1
tivozanib
1
repotrectinib
1
niraparib
1
lutetium Lu 177 dotatate
1
lenvatinib
1
iadademstat
1
durvalumab
1
cabozantinib
1
budigalimab
1
belinostat
1
Topotecan
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Neuroendocrine
×
pertuzumab
×
1 year
×
Clear all
No trials found.